NA
MED icon

Navellier & Associates’s Medifast MED Stock Holding History

Navellier & Associates’s Portfolio MED Stock Details MED Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-2,203
Closed -$283K – 291
2019
Q2 		$283K Sell
2,203
-24,924
-92% -$3.46M 0.04% 218
2019
Q1 		$3.46M Buy
27,127
+825
+3% +$105K 0.54% 47
2018
Q4 		$3.29M Buy
26,302
+2,450
+10% +$419K 0.56% 36
2018
Q3 		$5.28M Buy
23,852
+2,863
+14% +$580K 0.68% 38
2018
Q2 		$3.36M Buy
+20,989
New +$2.68M 0.47% 56

Other funds holding MED

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
MVP
Miller Value Partners Sarasota, Florida $423M AUM 49.14% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
EC
Engaged Capital Newport Beach, California $327M AUM 22.96% 1-Year Est. Return
PAMU
Pictet Asset Management (UK) London, United Kingdom $91.8B AUM 47.77% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $2.05B AUM 43.16% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Navellier & Associates's MED Position: Q3 2019 in Review

Navellier & Associates sold out of Medifast (MED) in Q3 2019, closing a stake of 2,203 shares — an estimated $283K sold.

Navellier & Associates first reported a position in MED in Q2 2018 and held it in 5 quarters. The position peaked at $5.28M in Q3 2018. 239 funds tracked by Wall St. Rank hold MED as of Q3 2019.

  • Navellier & Associates reported no remaining Medifast position as of Q3 2019 after selling out during the quarter.
  • Navellier & Associates sold 2,203 Medifast shares in Q3 2019, an estimated $283K.
  • Navellier & Associates first reported a position in Medifast in Q2 2018 and held it in 5 quarters.
  • Navellier & Associates's Medifast position peaked at $5.28M in Q3 2018.
  • 239 funds tracked by Wall St. Rank held Medifast as of Q3 2019.

Based on Navellier & Associates's 13F filing for Q3 2019, filed 16 Oct 2019.